✦ LIBER ✦

Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy

✍ Scribed by Han, K S; Joung, J Y; Kim, T S; Jeong, I G; Seo, H K; Chung, J; Lee, K H

Book ID: 109999351
Publisher: Nature Publishing Group
Year: 2007
Tongue: English
Weight: 103 KB
Volume: 98
Category: Article
ISSN: 0007-0920
DOI: 10.1038/sj.bjc.6604113

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of intermediate dose meth

Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma

✍ Paul M. Dodd; John A. McCaffrey; Madhu Mazumdar; Howard Scher; Vaia Vlamis; Gera 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 3 views

## Background: This study was undertaken to determine whether the use of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin as first-line therapy increases the proportion of major responders and overall survival in patients with unresectable or metastatic tra

Platinum-free combination chemotherapy i

Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma : A Phase I/II trial of gemcitabine, paclitaxel, and methotrexate

✍ Primo N. Lara Jr; Frederick J. Meyers; Lisa Y. Law; Nancy A. Dawson; Joan Housto 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 2 views

## Abstract ## BACKGROUND Platinum‐based regimens have improved response rates and survival in patients with advanced transitional cell carcinoma (TCC) of the urothelial tract. However, the toxicities of platinum‐based chemotherapy are considerable. Regimens with reduced toxicity that are applicab